Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 13/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616464 | 0.89 | CCR9 (0.61) | CCR9CCR2HSD17B2 | |
| SCHEMBL10241675 | 0.77 | CCR9 (0.60) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL1631935 | 0.75 | CCR9 (0.66) | CCR9CCR2HSD17B2 | |
| SCHEMBL2629495 | 0.73 | CCR9 (0.54) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL2616510 | 0.72 | CCR9 (0.66) | CCR9CCR2HSD17B2 | |
| SCHEMBL1630763 | 0.71 | CCR9 (0.63) | CCR9CCR2HSD17B2 | |
| SCHEMBL2616498 | 0.69 | CCR9 (0.79) | CCR9CCR2HSD17B2 | |
| Vercirnon SCHEMBL342225 | 0.66 | CCR9 (1.00) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL345093 | 0.66 | CCR9 (0.68) | CCR9CCR2HSD17B2 | |
| Vercirnon SCHEMBL15766988 | 0.65 | CCR9 (0.98) | CCR9CCR2LMNAHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CCR9 13/4885CCR2 1/4885LMNA 4876/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CCR9 13/4885CCR2 1/4885LMNA 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.